Long‐term response to crizotinib in a 17‐year‐old boy with treatment‐naïve ALK‐positive non‐small‐cell lung cancer. Issue 3 (28th January 2022)

• Record Type: Journal Article
• Authors: Megaro, Giacomina; Miele, Evelina; Spinelli, Gian Paolo; Alessi, Iside; Del Baldo, Giada; Cozza, Raffaele; Russo, Ida; De Pasquale, Maria Debora; Cefalo, Maria Giuseppina; Tomà, Paolo; Carai, Andrea; Di Ruscio, Valentina; De Ioris, Maria Antonietta; Mastronuzzi, Angela
• Is Part Of: Cancer reports. Volume 5:Issue 3(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-01-28
• Subjects: adenocarcinoma -- adolescence -- ALK -- crizotinib -- lung; Cancer -- Periodicals; 616.994005
• DOI: 10.1002/cnr2.1483
• Languages: English
• ISSNs: 2573-8348

Abstract

Abstract: Background: Lung cancer is the leading cause of cancer‐related death. NSCLC accounts for 80–90% of cases. In young patients, adenocarcinoma is the most frequent histotype and 3–7% expresses the rearrangement of ALK oncogene, sensitive to TKIs. Crizotinib is the first ALK inhibitor approved by the FDA. Case: We present a case of a 17‐year‐old male with metastatic treatment‐naïve ALK‐positive adenocarcinoma. He was treated with crizotinib and obtained a prolonged response with PFS of 33 months. Conclusion: Crizotinib can be extremely effective in adolescents with treatment‐naïve ALK‐positive NSCLC but fail to prevent a central nervous system relapse. Resistance mechanisms need to be investigated.